Neurocrine AI Stock Analysis
Want to see NBIX full AI Analyst Report?
Neurocrine (NBIX) AI Stock Analysis
Neurocrine
(NASDAQ:NBIX)
NBIX scores well primarily on strong financial performance (high profitability, low leverage, and robust free cash flow) and a constructive earnings update with raised INGREZZA guidance. The score is tempered by only moderate technical momentum, a valuation that is not clearly inexpensive (no dividend support), and guidance-related risks such as order timing and future pricing headwinds.
Neurocrine Key Performance Indicators (KPIs)
Revenue by SegmentShows how revenue is distributed across different business areas, highlighting which segments are driving growth and which may need strategic focus or improvement.
INGREZZA is the company’s core growth engine — sustained acceleration since 2023 drove management to raise full‑year INGREZZA guidance and underpins pro‑forma near‑$1B quarterly scale with the VYKAT XR deal. Smaller lines (Ongentys/Other, Collaboration) are inconsistent and immaterial, with Ongentys dropping to zero in recent quarters (likely reclassification/divestiture), so future revenue upside depends on Ingrezza durability, CRENESSITY uptake and successful integration/scale‑up of VYKAT XR; watch acquisition‑related cash use, GAAP charges and early‑launch churn as key near‑term risk factors.
The FlyNeurocrine (NBIX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $17.15B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.31M
- Price to Earnings (P/E)
- 24.5
- Beta (1Y)
- 0.53
- Revenue Growth
- 37.98%
- EPS Growth
- 61.95%
- Country
- US
- Employees
- 2,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Neurocrine Business Overview & Revenue Model
Company Description
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and market...
How the Company Makes Money
Neurocrine primarily makes money by selling its FDA-approved prescription medicines and recognizing related product revenue from U.S. and, where applicable, international markets. Its largest revenue stream is net product sales of INGREZZA, which the...
Neurocrine Earnings Call Summary
The call was strongly positive, supported by record third-quarter revenue and profitability, more than 40% year-over-year sales growth, growth across all three commercial products, increased INGREZZA guidance, substantial cash generation, and a broad pipeline with multiple 2027 catalysts. The main challenges were INGREZZA's expected fourth-quarter order-timing reversal and pricing headwinds, delayed VYKAT XR growth amid recent external events and ongoing safety and education work, and the discontinuation of NBI-'986. Highlights significantly outweighed lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Neurocrine raised full year INGREZZA guidance to $2.9 billion to $2.925 billion, with 2026 prescription growth expected to be in the high-teens; for the fourth quarter, underlying TRx growth is expected to be somewhere in the mid-teens. For 2027, the company expects continued double-digit INGREZZA volume growth to more than offset anticipated mid- to high single-digit net pricing headwinds, with roughly mid- to high single-digit price concession, and expects 2027 access to be at least as good as this year, when about 70% of Medicare lives were covered under contracting executed in 2025; formal 2027 sales guidance will be provided in February. For VYKAT XR, the company anticipates a return to growth, but it might be a little bit more delayed, and said every quarter it wants to see more patients on than the prior quarter. The company plans to initiate a VYKAT XR study in 2027 in people with PWS and complex health issues, expects Phase III data readouts for osavampator in major depressive disorder and direclidine in schizophrenia in 2027, and remains on track to deliver 6 Phase Is, along with 5 new Phase II starts this year.
Neurocrine Financial Statement Overview
Summary
Strong overall fundamentals: revenue scaled materially (to $3.70B TTM) with improving net margins (~19% TTM), low leverage (debt-to-equity ~0.10 TTM), and excellent cash generation (FCF $1.04B TTM and closely aligned with earnings). Key watch-outs are the recent slowdown in revenue growth versus prior years and historical variability in operating profitability/cash flow coverage.
Income Statement
88Very PositiveBalance Sheet
86Very PositiveCash Flow
90Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.70B | 2.86B | 2.36B | 1.89B | 1.49B | 1.13B |
| Gross Profit | 3.62B | 2.81B | 2.32B | 1.85B | 1.47B | 1.12B |
| EBITDA | 946.60M | 666.60M | 639.70M | 416.10M | 236.60M | 138.10M |
| Net Income | 702.50M | 478.60M | 341.30M | 249.70M | 154.50M | 89.60M |
Balance Sheet | ||||||
| Total Assets | 5.63B | 4.63B | 3.72B | 3.25B | 2.37B | 2.07B |
| Cash, Cash Equivalents and Short-Term Investments | 737.90M | 1.48B | 1.08B | 1.03B | 989.30M | 711.30M |
| Total Debt | 392.30M | 415.30M | 455.10M | 428.40M | 262.90M | 440.40M |
| Total Liabilities | 1.75B | 1.38B | 1.13B | 1.02B | 660.90M | 698.50M |
| Stockholders Equity | 3.88B | 3.25B | 2.59B | 2.23B | 1.71B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 1.04B | 748.70M | 557.20M | 361.60M | 322.90M | 233.10M |
| Operating Cash Flow | 1.07B | 782.70M | 595.40M | 389.90M | 339.40M | 256.50M |
| Investing Cash Flow | -705.60M | -264.40M | -126.80M | -467.10M | -177.10M | -130.20M |
| Financing Cash Flow | -60.40M | -38.30M | -486.70M | 65.30M | -234.30M | 27.40M |
Neurocrine Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NBIX, the sentiment is Positive. The current price of 169.40 is above the 20-day moving average (MA) of 152.72, above the 50-day MA of 148.40, and above the 200-day MA of 148.73, indicating a bullish trend. The MACD of 7.07 indicates Negative momentum. The RSI at 67.48 is Neutral, neither overbought nor oversold. The STOCH value of 93.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NBIX.
Neurocrine Risk Analysis
Neurocrine disclosed 51 risk factors in its most recent earnings report. Neurocrine reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksNeurocrine Peers Comparison
Overall Rating
- NBIX80Outperform
HRMY77Outperform
ACAD72Outperform
PRAX71Outperform
AXSM47Neutral
XENE46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| NBIX | 80Outperform | $17.65B | 24.47 | 19.74% | ― | 37.98% | 61.95% |
| HRMY | 77Outperform | $2.01B | 11.02 | 18.55% | ― | 19.79% | -4.89% |
| ACAD | 72Outperform | $3.17B | 8.47 | 28.03% | ― | 14.82% | 36.49% |
| PRAX | 71Outperform | $9.68B | -25.73 | -29.41% | ― | -100.00% | 0.75% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AXSM | 47Neutral | $7.85B | -47.54 | -189.73% | ― | 54.16% | 34.51% |
| XENE | 46Neutral | $4.14B | -8.82 | -39.80% | ― | -100.00% | -21.09% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NBIX | Neurocrine Biosciences | 169.40 | 25.84 | 18.00% | |
| ACAD | ACADIA Pharmaceuticals Inc. | 18.14 | -5.87 | -24.45% | |
| XENE | Xenon Pharmaceuticals | 40.99 | 0.38 | 0.95% | |
| AXSM | Axsome Therapeutics Inc. | 144.37 | -1.19 | -0.82% | |
| HRMY | Harmony Biosciences Holdings, Inc. | 33.80 | -0.19 | -0.56% | |
| PRAX | Praxis Precision Medicines, Inc. | 324.76 | 127.18 | 64.37% |
Neurocrine Corporate Events
Neurocrine Names Eiry Roberts as New Chief Medical Officer
NeutralOn September 25, 2026, Neurocrine Biosciences and Chief Medical Officer Sanjay Keswani, M.D., mutually agreed to end his service, with Keswani entitled to severance benefits under the company’s existing executive severance plan, reflecting an orderly...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026